Drug intelligence / Profile preview

SBT-500

Development stage: Preclinical
Lead developer: Singh Biotechnology
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

SBT-500 is a prophylactic single-domain antibody (nanobody) candidate developed by Singh Biotechnology for the prevention of SARS-CoV-2 infection and its variants. Utilizing the company's proprietary VHH platform, SBT-500 is engineered to target the spike protein of the virus, thereby blocking its interaction with host cell receptors and preventing viral entry. The drug was presented at the 2021 Military Health System Research Symposium (MHSRS) as a potential countermeasure against COVID-19, demonstrating efficacy in preventing infection across multiple variants of the virus.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SBT-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-500.

Explore the full profile